You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
SA FasL engineered human islets as a novel product for the treatment of type diabetesSBC: FasCure Therapeutics LLC Topic: NIDDK
PROJECT SUMMARY Type diabetes T D is a chronic autoimmune disorder that affects of population worldwide Exogenous insulin treatment is the standard of care for T D but often negatively affects the quality of life and is ineffective in preventing recurrent hyperglycemia episodes and chronic complications Recent studies show that human islet allografts can restore long term normoglycemia ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant systemSBC: FasCure Therapeutics LLC Topic: NIAID
DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
TheraBracelet: The first and only wearable to instantly improve stroke hand functionSBC: TheraBracelet, Inc. Topic: NICHD
Project SummaryPost stroke hand impairment is highly prevalent and severely restricts functional ability and independenceIn facteveryseconds a new stroke occursand stroke is recognized as the leading cause of long term disabilityYetthere is no assistive device to help hand function at homeevery dayduring activities of daily livingExisting devices such as hand opening orthoses are expensivee gMyomo ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
A new generation of targeted therapeutics for the treatment of cancerSBC: NERX BIOSCIENCES, INC. Topic: NCI
DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
A Novel Probiotic Platform to Treat Necrotizing EnterocolitisSBC: MONON BIOVENTURES LLC Topic: 300
PROJECT SUMMARY Probiotics hold enormous potential for promoting human health and treating disease One major hurdle to many probiotic products is their lack of persistence in the gut Monon Bioventures MBV and their research partners at the Research Institute at Nationwide Childrenandapos s Hospital RINCH are developing a novel enhanced tunable technology called ProNextTM that allows for a ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
Commercialization of a Novel Therapeutic for Alzheimer's DiseaseSBC: CoPlex Therapeutics, LLC Topic: NIA
ABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
Lentiviral Vector for the treatment of Fanconi AnemiaSBC: Rimedion, Inc. Topic: NHLBI
DESCRIPTIONprovided by applicantIn this Phase II STTR application Rimedion seeks to commercialize a novel treatment for patients suffering from Fanconi anemia and request funding for a Phase I II clinical trialThe product will utilize a HIVbased lentiviral vector expressin the Fanconi anemia A proteinThe strong scientific support for this approached is strengthened by a successful Phase I STTRThe ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
Personalized dosing of dichloroacetate for the treatment of rare and common diseasesSBC: Medosome Biotec, LLC Topic: NICHD
Pyruvate dehydrogenase complexPDCdeficiencyPDCDis a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncatedTreatment of PDCD remains a seriousunmetchallengeThere has never been a controlled trial of any intervention for PDCDthusthere is no proven therapy for affected patientsDichloroacetateDCArepresents the first targeted therapy for ...STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
Nonlinear Computation Tool to Chart Trajectories of Bipolar DisorderSBC: Biomedical Development Corporation Topic: 103
DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health